4D Path

United States · Healthtech · Biotech · AI · Enterprise software

Digital biomarkers designed to predict cancer treatment response from routine biopsy images.

Reading tumour dynamics from pathology slides

4D Path’s Q-Plasia OncoReader platform analyzes digitized H&E-stained biopsy images. Its physics-informed approach quantifies cell-cycle changes and features of the tumour microenvironment to generate treatment-response signatures.

The cloud-based workflow produces predictive reports for clinical research and drug-development partnerships. It supports work such as selecting trial cohorts and studying resistance to treatment across different cancers and therapies.

Funding history

1 round · 0 with disclosed amounts
AnnouncedRoundAmountInvestors
StrategicUndisclosedParticipants not disclosed
Sources4dpath.com ↗